| Identification | Back Directory | [Name]
SULFANILYLUREA | [CAS]
547-44-4 | [Synonyms]
a435
A 435
Urenil
Uramid
Uractyl
Euvernil
Sulfaurea
Urosulfan
NSC 78438
NSC 78438Q
Urosulfane
Sulphaurea
Sulfanyluree
A 435 (amide)
sulfacarbamide
sulfanilyl-ure
SULFANILYLUREA
Sulphacarbamide
1-Sulfanilylurea
4-Sulfacarbamide
Sulfanilcarbamid
Sulfanylharnstoff
Urea, sulfanilyl-
N-Sulfanilcarbamide
p-Aminobenzenesulfonylurea
(4-aminophenyl)sulfonylurea
[(p-Aminophenyl)sulfonyl]urea
1-(4-azanylphenyl)sulfonylurea
[(4-aMinobenzene)sulfonyl]urea
1-(4-Aminobenzenesulfonyl)urea
Sulfanilamide, N(sup1)-carbamoyl-
Sulphaminoic acid N-carbamoylamide
N-[(4-Aminophenyl)sulphonyl]urea (S
4-AMino-N-carbaMoylbenzenesulfonaMide
4-amino-n-(aminocarbonyl)-benzenesulfonamid
4-Amino-N-(aminocarbonyl)benzenesulfonamide
Benzenesulfonamide,4-amino-N-(aminocarbonyl)-
Benzenesulfonamide, 4-amino-N-(aminocarbonyl)-
1-Amino-4-([(aminocarbonyl)amino]sulfonyl)benzene | [EINECS(EC#)]
208-922-7 | [Molecular Formula]
C7H9N3O3S | [MDL Number]
MFCD00025437 | [MOL File]
547-44-4.mol | [Molecular Weight]
215.23 |
| Chemical Properties | Back Directory | [Melting point ]
146-148° (slight dec) | [density ]
1.4565 (rough estimate) | [refractive index ]
1.6630 (estimate) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
DMSO : ≥ 28 mg/mL (130.09 mM) | [form ]
Solid | [pka]
pKa 1.78(H2O
t = 25
I = 0.05) (Uncertain);5.42(H2O
t = 25
I = 0.05) (Uncertain) | [color ]
White to off-white | [Water Solubility ]
2.333g/L(20 ºC) | [InChI]
InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11) | [InChIKey]
WVAKABMNNSMCDK-UHFFFAOYSA-N | [SMILES]
C1(S(NC(N)=O)(=O)=O)=CC=C(N)C=C1 |
| Hazard Information | Back Directory | [Description]
Sulfacarbamide is a blood sugar-lowering drug, also acting on the vegetative nervous system. | [Chemical Properties]
White solid | [Uses]
antibacterial | [Definition]
ChEBI: Sulfacarbamide is a sulfonamide and a member of benzenes. | [World Health Organization (WHO)]
Sulfacarbamide, a sulfonamide anti-infective agent, was
introduced in the 1940's for the treatment of bacterial infections. The importance of
sulfonamides has subsequently decreased as a result of increasing bacterial
resistance and their replacement by antibiotics which are generally more active
and less toxic. The Sulfacarbamide are known to cause serious adverse effects
such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema
multiforma and dangerous adverse reactions affecting blood formation such as
agranulocytosis and haemolytic or aplastic anaemia. Sulfacarbamide still remains
available in at least one country for the treatment of urinary infections. | [Mechanism of action]
Sulfonylureas bind to and inhibit the ATP-sensitive potassium channels (K) on the pancreatic beta cells. As a result, potassium efflux decreases, and the beta-cell membrane depolarizes. Membrane depolarization causes calcium channels to open, leading to calcium influx and increased intracellular calcium, which stimulates insulin secretion from the pancreatic beta cells. Sulfonylureas cause insulin release regardless of blood glucose levels. | [storage]
Store at -20°C |
|
|